Capecitabine, oxaliplatin and radiotherapy: A phase IB neoadjuvant study for esophageal cancer with gene expression analysis

  • Javle M
  • Yang G
  • Nwogu C
 et al. 
  • 10

    Readers

    Mendeley users who have this article in their library.
  • 10

    Citations

    Citations of this article.

Abstract

PURPOSE: To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer.

PATIENTS AND METHODS: Oxaliplatin (85 mg/m(2)) administered on days 1, 15, and 29. Capecitabine administered twice daily 5 days weekly; dose levels (DL) were 1, 1000; 2, 1250; and 3, 1500 mg/m(2) with 50.4 Gy radiation.

RESULTS: Dose-limiting toxicity was reached at DL 3. Carboxylesterase expression in day 2 tumor specimens and induction correlated with response (p
CONCLUSION: The maximal tolerated dose was 85 mg/m(2) of oxaliplatin, 1,250 mg/m(2)/day of capecitabine, and 50.4 Gy of radiation.

Author-supplied keywords

  • Capecitabine
  • Esophageal neoplasms
  • Gene expression
  • Neoadjuvant therapy
  • Oxaliplatin

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Milind M. Javle

  • Gary Yang

  • Chumy E. Nwogu

  • Gregory E. Wilding

  • Linda O'Malley

  • Sanjay Vinjamaram

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free